Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Stomach Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 6Mitotane 5Cisplatin 5cabozantinib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Doxorubicin 3sodium thiosulfate 2relacorilant 2cixutumumab 2cemiplimab 2camrelizumab 2apatinib 2Radiotherapy 2Nivolumab 2Ipilimumab 2Etoposide 2Cytoreduction Surgical Procedures 2milademetan 1lenvatinib 1gossypol acetic acid 1dostarlimab 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Tamoxifen 1Suramin 1Sunitinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adrenocortical Carcinoma × N-Ac-CHAVC-NH2 × Clear all
NCT00264433 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Adherex Technologies, Inc.

Phase 2 Completed
EndocrineGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡